Jeffrey M. Goldberg

Former President and Chief Executive OfficeratSpyre Therapeutics· In proxies 2022–2023

Pay in FY2023-55% from the year before · Spyre Therapeutics stock +91.3% the same year

Jeffrey M. Goldberg was paid $830.2K in FY2023 (Dec), down 55%. Spyre Therapeutics stock rose 91.3% that year.

Pay$100 in the stock at the end of FY21 → $18

Pay is from the Summary Compensation Table of each Spyre Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

SYRE
Spyre TherapeuticsPublic company · 4 yr
- Former President and Chief Executive Officer2022 – Present · 4 yrStock in role -6%

Roles come from the proxy statements of each company.

Activity

Pay
Spyre Therapeutics President pay fell 55% to $830.2K. The stock rose 91% in FY2023 (Dec).
DEF 14AApr 1, 2024

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?